Related Experiment Video

Updated: Jun 19, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy

Chad L Deal1, Michael W Draper

  • 1Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunology Diseases/A50, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. dealc@ccf.org.

Women'S Health (London, England)
|October 7, 2009
PubMed

Insights

Selective estrogen-receptor modulators like raloxifene effectively prevent osteoporosis and reduce breast cancer risk. Long-term studies confirm raloxifene

Area of Science:

  • Pharmacology
  • Endocrinology
  • Oncology

Background:

  • Selective estrogen-receptor modulators (SERMs) exhibit unique estrogen receptor binding affinities, influencing gene transcription.
  • Raloxifene, a SERM, is FDA-approved for preventing and treating postmenopausal osteoporosis.

Purpose of the Study:

  • To provide an updated analysis of clinical trial data for raloxifene.
  • To evaluate the long-term efficacy and safety of raloxifene in postmenopausal women.

Main Methods:

  • Analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial and its continuation, the Continuing Outcomes Relevant to Evista (CORE) trial.
  • Assessment of raloxifene's effects on skeletal health, cardiovascular events, and breast cancer incidence over 4 and 8 years.

Main Results:

  • Raloxifene significantly decreased vertebral fracture risk in osteoporotic women.
  • A significant reduction in breast cancer risk was observed in women treated with raloxifene compared to placebo.
  • Raloxifene showed similar skeletal and cardiovascular effects to placebo, with no increased risk of uterine pathologies.
  • Adverse events included increased hot flashes, leg cramps, and a higher risk of venous thromboembolic events.

Conclusions:

  • Raloxifene is effective for osteoporosis prevention and treatment and reduces breast cancer risk in postmenopausal women.
  • Long-term use of raloxifene demonstrates sustained efficacy with a manageable safety profile, though risks of VTE and vasomotor symptoms exist.

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.